Gepotidacin is an exciting new oral antibiotic that's currently in Phase III trials, targeting uncomplicated urinary tract infections (UTIs) and urogenital gonorrhoea. 1.It works by blocking two essential topoisomerase enzymes that are vital for bacterial DNA replication. The early results from Phase II trials are looking quite promising, and if it gets approved, it could be the first new oral antibiotic for UTIs in over twenty years! To get a better understanding of how it interacts with other medications, Phase I studies were carried out with healthy volunteers to assess gepotidacin's drug drug interaction (DDI) profile. When taken with the CYP3A4/P-glycoprotein (P-gp) inhibitor itraconazole, there was a modest increase in the area under the curve (AUC) by about 48–50%. On the other hand, rifampicin, a strong CYP3A4 inducer, significantly reduced gepotidacin's plasma AUC by 52%, indicating a moderate DDI. No major interactions were observed with cimetidine, although some biomarkers suggested a partial inhibition of organic cation transporters. Interestingly, gepotidacin didn’t act as a DDI perpetrator for P-gp or CYP3A4, but it did slightly elevate the plasma levels of digoxin and showed weak inhibition of CYP3A4 when combined with midazolam. These insights will be crucial for ensuring the safe clinical use of gepotidacin alongside other medications.
Gürkan Kıran (Sun,) studied this question.